Biotech
The Scaling Crisis in Cell and Gene Therapy

The Scaling Crisis in Cell and Gene Therapy

There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...

read more
The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Kailera Therapeutics IPO: A $625M Signal for Biotech

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
Longevity Biotech: Separating the Science from the Hype

Longevity Biotech: Separating the Science from the Hype

The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...

read more
Natural Diamonds in Healthcare

Natural Diamonds in Healthcare

When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...

read more
New Report Highlights Why CGTs Still Struggle at Market Access

New Report Highlights Why CGTs Still Struggle at Market Access

Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...

read more
Why a New Era of Medical Innovation is Taking Shape

Why a New Era of Medical Innovation is Taking Shape

Over the next decade, modern medicine is poised to undergo a redefinition that has not been seen in generations. The surge in innovation, transformational scientific discoveries and rapidly maturing technologies is redefining patient outcomes. The biotech industry is...

read more